CD19 and lymphoma: Kyverna Therapeutics’ fully human CD19 CAR with a CD28 costimulatory domain, tested for safety and efficacy in lymphoma [66], enters a Phase 2 trial [67] with a cyclophosphamide and fludarabine lymphodepletion regimen.